期刊
BIOCHIMICA ET BIOPHYSICA ACTA-GENE REGULATORY MECHANISMS
卷 1799, 期 10-12, 页码 775-787出版社
ELSEVIER SCIENCE BV
DOI: 10.1016/j.bbagrm.2010.05.004
关键词
Inflammation; NF-kappa B; Small molecule inhibitors; Therapeutics
资金
- Clayton Foundation for Research
- National Institutes of Health (NIH) [CA-16 672, CA-124787-01A2]
- Center for Targeted Therapy of M.D. Anderson Cancer Center
- NATIONAL CANCER INSTITUTE [P30CA016672, P01CA091844, P01CA124787] Funding Source: NIH RePORTER
Because nuclear factor-kappa B (NF-kappa B) is a ubiquitously expressed proinflammatory transcription factor that regulates the expression of over 500 genes involved in cellular transformation, survival, proliferation, invasion, angiogenesis, metastasis, and inflammation, the NF-kappa B signaling pathway has become a potential target for pharmacological intervention. A wide variety of agents can activate NF-kappa B through canonical and noncanonical pathways. Canonical pathway involves various steps including the phosphorylation, ubiquitination, and degradation of the inhibitor of NF-kappa B (I kappa B alpha), which leads to the nuclear translocation of the p50-p65 subunits of NF-kappa B followed by p65 phosphorylation, acetylation and methylation, DNA binding, and gene transcription. Thus, agents that can inhibit protein kinases, protein phosphatases, proteasomes, ubiquitination, acetylation, methylation, and DNA binding steps have been identified as NF-kappa B inhibitors. Because of the critical role of NF-kappa B in cancer and various chronic diseases, numerous inhibitors of NF-kappa B have been identified. In this review, however, we describe only small molecules that suppress NF-kappa B activation, and the mechanism by which they block this pathway. (C) 2010 Elsevier B.V. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据